LOCACORTEN VIOFORM 3 % — DIN 00074462
CLIOQUINOL : 3 % FLUMETHASONE PIVALATE : 0.02 % · ENDO OPERATIONS LTD. · CREAM · wholesale supply in Canada
Health Canada status: MARKETED
What is LOCACORTEN VIOFORM?
LOCACORTEN VIOFORM 3 % contains CLIOQUINOL : 3 % FLUMETHASONE PIVALATE : 0.02 %. It is listed in the Health Canada Drug Product Database under DIN 00074462, held by ENDO OPERATIONS LTD., supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 19-Dec-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LOCACORTEN VIOFORM used for?
Corticosteroid-responsive inflammatory skin disorders complicated by bacterial/fungal infections (e.g., seborrheic/atopic/contact dermatitis, intertrigo, pyoderma) and dermatomycosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Flumetasone And Antibiotics in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Flumetasone And Antibiotics, across 2 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ENDO OPERATIONS LTD. | 1 | 1 | LOCACORTEN VIOFORM | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 1 | 0 | LOCACORTEN VIOFORM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 3 % |
|---|---|
| Dosage form | CREAM |
| Route | TOPICAL |
| Pack configuration (monograph) | Tubes of 30 g and 50 g. |
| Storage | Store between 15-30°C. Protect from heat and freezing. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Flumetasone And Antibiotics |
|---|---|
| ATC code | D07CB05 |
| AHFS class | 84:04.08.92 ; 84:06.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00074462 |
|---|---|
| DIN (unpadded, as printed on some documents) | 74462 |
| Brand name | LOCACORTEN VIOFORM |
| Generic / active ingredient | CLIOQUINOL : 3 % FLUMETHASONE PIVALATE : 0.02 % |
| Market authorization holder | ENDO OPERATIONS LTD. |
| Health Canada schedule | Prescription |
| ATC code | D07CB05 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D07CB |
| Current status | MARKETED |
| Status date | 19-Dec-2025 |
| Original market date | 1968-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply to affected areas in a thin layer 2 to 3 times daily. Use under occlusive dressings is not recommended. Discontinue if no improvement within 1 week.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Viral skin infections, tuberculosis of skin, syphilis, rosacea, acne vulgaris, perioral dermatitis; hypersensitivity to ingredients/iodine; ulcerated areas; eye application; children <2 years.
Warnings and precautions
Avoid contact with eyes/conjunctiva. Do not use in external auditory canal if eardrum is perforated. Risk of systemic effects/adrenal suppression if used on large areas or under occlusion.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| LOCACORTEN VIOFORM | 3 % | OINTMENT | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 00074470 |
2 · Same class — other molecules in ATC D07CB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Triamcinolone And Antibiotics | ARISTOFORM R CRM 0.1% · KENACOMB CREAM · KENACOMB MILD CREAM · KENACOMB MILD OINTMENT · +7 more | 11 | 4 | Yes |
| Flumetasone And Antibiotics | LOCACORTEN VIOFORM | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D07C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D07CA | Hydrocortisone And Antibiotics · Methylprednisolone And Antibiotics | 8 | 2 |
| D07CC | Betamethasone And Antibiotics · Fluocinonide And Antibiotics | 6 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.